EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Twelve-Month CPAP Therapy Modulates BDNF Levels in Patients with Severe Obstructive Sleep Apnea: Implications for Metabolic and Treatment Compliance

Urszula Karwowska, Aleksandra Kudrycka, Karol Pierzchała iD, Robert Stawski iD, Hanna Jerczyńska iD, Piotr Białasiewicz, Wojciech Kuczyński iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Urszula Karwowska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Sleep Apnea, Obstructive, Continuous Positive Airway Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the regulation of synaptic plasticity and metabolic processes, including glucose metabolism and insulin sensitivity. In patients with obstructive sleep apnea (OSA), recurrent episodes of intermittent hypoxia may stimulate BDNF expression as a compensatory neuroprotective response. OSA is associated with metabolic disturbances, such as increased insulin resistance and a higher risk of type 2 diabetes. Continuous positive airway pressure (CPAP) therapy may influence both BDNF levels and metabolic outcomes. The aim of this study was to evaluate changes in BDNF concentration and glucose metabolism in patients with OSA, with particular emphasis on the effect of long-term CPAP therapy. Sixty-six adult patients with OSA confirmed by polysomnography were enrolled and divided into severe (s-OSA) and non-severe (ns-OSA) groups. Fasting blood samples were collected to measure glucose, insulin, and BDNF concentrations. Patients with s-OSA were re-evaluated after 12 months of CPAP therapy and further classified as compliant (sc-OSA) or non-compliant (snc-OSA) based on recorded device usage. The same biochemical parameters were assessed after the 12-month follow-up. Baseline BDNF levels were significantly higher in the s-OSA group compared to the ns-OSA group (20.1 ng/mL vs. 8.1 ng/mL, p = 0.02) and correlated with the apnea–hypopnea index (AHI, r = 0.38, p = 0.02). In the nsc-OSA group, BDNF concentrations increased significantly after 12 months (16.2 ng/mL vs. 35.5 ng/mL, p < 0.001), while no significant change was observed in the sc-OSA group (24.4 ng/mL vs. 27.4 ng/mL, p = 0.33). Among sc-OSA patients, a significant improvement in insulin resistance was noted, although no significant changes were observed in fasting glucose or insulin levels. Increased BDNF levels were observed in patients with s-OSA compared to ns-OSA. Compliant CPAP therapy was associated with reduced insulin resistance and no further BDNF increase, in contrast to non-compliance, suggesting a beneficial effect of CPAP on glucose metabolism and BDNF regulation. These findings support the hypothesis that both neurotrophic and metabolic responses in OSA may be modulated by disease severity and therapy adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorSleep Apnea, ObstructiveContinuous Positive Airway PressureHumansMaleFemaleMiddle AgedAdultBlood GlucosePatient ComplianceInsulinInsulin ResistancePolysomnography

Stichwörter der Autor:innen

CPAP therapybrain-derived neurotrophic factorglucose metabolisminsulin resistanceneurocognitive impairmentobstructive sleep apnea

Substanzen

Brain-Derived Neurotrophic FactorBlood GlucoseBDNF protein, humanInsulin

Autor:innen und Institutionen

  • Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.
  • Department of Clinical Physiology, Medical University of Lodz, 92-215 Lodz, Poland.
  • Central Scientific Laboratory (CoreLab), Medical University of Lodz, 92-215 Lodz, Poland.

ORCID-Profile: Karol Pierzchała, Robert Stawski, Hanna Jerczyńska, Wojciech Kuczyński

Förderung

  • Medical University of Lodz

Zitieren

APA

Karwowska, U., Kudrycka, A., Pierzchała, K., Stawski, R., Jerczyńska, H., Białasiewicz, P., & Kuczyński, W. (2025). Twelve-Month CPAP Therapy Modulates BDNF Levels in Patients with Severe Obstructive Sleep Apnea: Implications for Metabolic and Treatment Compliance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125855

Vancouver

Karwowska U, Kudrycka A, Pierzchała K, Stawski R, Jerczyńska H, Białasiewicz P, et al. Twelve-Month CPAP Therapy Modulates BDNF Levels in Patients with Severe Obstructive Sleep Apnea: Implications for Metabolic and Treatment Compliance. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125855

BibTeX
@article{Karwowska2025,
  author = {Karwowska, Urszula and Kudrycka, Aleksandra and Pierzchała, Karol and Stawski, Robert and Jerczyńska, Hanna and Białasiewicz, Piotr and Kuczyński, Wojciech},
  title = {Twelve-Month CPAP Therapy Modulates BDNF Levels in Patients with Severe Obstructive Sleep Apnea: Implications for Metabolic and Treatment Compliance},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125855}
}
Kostenlos starten →